The Trump administration is reportedly crafting plans that would allow state-licensed compounding pharmacies to prepare seven specific peptide treatments for insomnia, obesity, and wound healing, according to a report published October 8.
The plan would use interim enforcement discretion—a mechanism that does not formally approve the peptides but signals that regulators do not intend to take enforcement action against pharmacies preparing them. The approach would create a temporary legal pathway for compounds that currently lack FDA approval.
The reported plan comes months after FDA career scientists stated in late June that there is insufficient evidence on the safety and effectiveness of these peptides. However, an advisory committee that includes members who promote peptide therapies voted to recommend six of the seven compounds under consideration.
What happened
According to reporting by the Australian Financial Review, the Trump administration is developing guidance that would permit compounding pharmacies to prepare seven peptide treatments under interim enforcement discretion. The specific peptides are said to target insomnia, obesity, and wound healing.
The plan has not been publicly announced, and its timing remains unclear. The status of the seventh compound, which the advisory committee did not recommend, is not specified in the reporting.
FDA career scientists had previously raised concerns about the evidence base for these peptides. An advisory committee with members who promote peptide therapies voted to recommend six of the seven compounds, creating a tension between scientific staff review and the advisory process.
Why it matters
If enacted, the policy would represent a significant shift in peptide regulation. State-licensed compounding pharmacies could gain a temporary legal pathway to produce peptides that have not completed FDA’s approval process, during which claims of efficacy remain incompletely tested.
The change could affect enforcement priorities for hundreds of telehealth clinics and peptide sellers currently operating in a gray regulatory area. State pharmacy boards, FDA enforcement personnel, and patients would all be affected by any shift in approach.
The policy also highlights an ongoing tension within FDA: career scientists have flagged insufficient safety and effectiveness data, while an advisory committee with peptide proponents has recommended most of the compounds.
What to watch next
- Whether and when the Trump administration publicly announces the guidance
- How FDA reconciles its scientists’ safety concerns with the advisory committee’s recommendations
- Whether all seven peptides or only the six recommended compounds receive enforcement discretion
- How state pharmacy boards and telehealth clinics respond to any new enforcement posture
Sources
Industry information only. Not medical or legal advice.
